--- title: Vescell Home description: Hemostemix is currently recruiting patients to participate in the VesCell (ACP-01) Phase I clinical study for Vascular Dementia.  --- [![VesCell Logo smaller 080125](https://www.vescell.health/hubfs/VesCell%20Logo%20smaller%20080125.png)](https://www.vescell.health) ![menu](https://f.hubspotusercontent40.net/hubfs/7479797/menu.png) ![close_24px](https://7479797.fs1.hubspotusercontent-na1.net/hubfs/7479797/close_24px.svg) - [Story](https://www.vescell.health/our-story) - [Memberships](https://www.vescell.health/memberships) - [Events](https://www.vescell.health/events) - [Registry](https://www.vescell.health/registry) - GLOBAL - [Story](https://www.vescell.health/our-story) - [Memberships](https://www.vescell.health/memberships) - [Events](https://www.vescell.health/events) - [Registry](https://www.vescell.health/registry) - GLOBAL [Request Appointment](https://calendly.com/clawrence-hemostemix) # Revive Your Vascular Health. #### VesCell Health is the world's premier vascular longevity center.   #### Healthy blood flow holds the key to your best years ahead.  Our curated memberships deliver advanced diagnostics, regenerative therapies and biologic optimization to extend your vascular healthspan and overall longevity. ### Request Appointment ## How it works #### Vascular Health Plans, Personalized for You. #### Do you suffer from any of these conditions? A smarter, more powerful way to explore the VesCell Health protocol to restore vascular health..  Regenerative medicine may be available for qualified patients in certain jurisdictions.   Advancing to Phase III Study ##### Chronic Limb Threatening Ischemia Non-healing ulcers and wounds Phase I Study ##### Peripheral Artery Disease (PAD) Phase I Study ##### Chronic Pain, Severe Angina Phase I Study ##### Ischemic Cardiomyopathy Left Ventricular Dysfunction, Low ejection fraction Phase I Study ##### Non-Ischemic Dilated Cardiomyopathy Phase I Study ##### Vascular Dementia Cognitive Decline Following a Stroke Phase I Study ##### Total Body Ischemia Phase I Study ##### Congestive Heart Failure 498 Patients Treated 22 Years of Clinical Development 8 Indications 90 Patents ## Autologous Stem Cell Therapy based on Industry Leading Clinical Research - ##### ACP-01 is not FDA approved.  It is an investigational, angiogenic stem cell therapy derived from a patient’s own blood.  - ##### Personalized therapy is designed to enhance blood flow and may help restore vascular health. - ##### VesCell Health Membership offers hope through clinical trials, innovative access, and compassionate use programs. [See if you qualify](https://calendly.com/clawrence-hemostemix) ![Family](https://www.vescell.health/hs-fs/hubfs/Family%20pic%20for%20website.jpg?width=1787&height=1416&name=Family%20pic%20for%20website.jpg "Family") ## How do angiogenic stem cells work? ###### Find VesCell migrates to areas of decreased blood flow (Ischemia) ###### Embed VesCell embeds into injured tissues and repopulates injured tissue. ###### Release VesCell releases growth factors and reduces inflammation. ###### Generate Generates new blood vessels to improve blood flow. ![ACP-01 Science](https://www.vescell.health/hubfs/MOA.png "ACP-01 Science") ### Is Stem Therapy Right for You? If you or a loved one have no-option Chronic Limb Threatening Ischemia (CLI) with non-healing ulcers, Stem Therapy may offer hope through our Expanded Access Program or clinical trials. Take the first step to learn more and see if you qualify for this investigational therapy. ![Before_CLI](https://www.vescell.health/hubfs/Before_CLI-1.jpg "Before_CLI") ![After_CLI](https://www.vescell.health/hubfs/After_CLI.jpg "After_CLI") ### **Now Available: A New Path for No-Option CLI** ##### For those facing critical limb threatening ischemia (CLI) with no other treatment options, VesCell offers hope. ##### This investigational autologous stem cell therapy is designed to improve blood flow in the lower legs and feet, heal ulcers, and reduce the risk of amputation and mortality. ##### Critical limb ischemia (CLI) is a subset of Peripheral Artery Disease (PAD). ##### Backed by Phase II clinical trial data, VesCell is an investigation treatment for patients with severe CLI. [Reach a Care Team Navigator](https://calendly.com/clawrence-hemostemix) ###### What does “No option” mean? “No option” patients are those without suitable surgical revascularization options, and often face major amputations, or severe morbidity (Angina, or Cardiomyopethy). ###### What are the signs of Critical Limb Ischemia? Symptoms of peripheral arterial disease, pain while at rest, or gangrene. ### Re-Examination of Phase II ACP NO-CLI Trial Data ###### Re-examination of patients who presented with Wound Ulcers before administration of ACP-01 (21 Treatment, 8 Placebo)  - ###### **96.7% Ulcer Size Reduction** ###### Ulcer size in the treated group decreased from a mean of 1.46 cm2 to 0.48 mm2 (p = 0.01) by 3 months - ###### **Amputation Rate Reduction** ###### 93.5% of treated patients saved limbs, compared to 90.5% placebo patients lost their their limb from amputation in the Phase 2 study. - ###### **4.8% Mortality Rate Reduction** ###### VesCell reduced mortality to 4.8% compared to 12.5% in the placebo group at one year. ###### Further studies, more appropriately powered, are warrented. ###### *VesCell is investigational and not FDA-approved.  Safety and efficacy have not been established.* [See Scientific Library Here](https://hemostemix.com/scientific-publications/) ###### Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI FC Henderson, I Sarel, K Tuchman, S Lewis… - Journal, 2024 ###### Autologous Angiogenic Cell Precursors-A Molecular Strategy for the Treatment of Heart Failure: Response to Biocardia's Cardiamp HFFC Henderson, K Tuchman, I Sarel - Journal ISSN, 2025 ![Logo_Cell Soc](https://www.vescell.health/hs-fs/hubfs/Logo_Cell%20Soc.png?width=182&height=100&name=Logo_Cell%20Soc.png) ![Logo_Cyto](https://www.vescell.health/hs-fs/hubfs/Logo_Cyto.png?width=338&height=50&name=Logo_Cyto.png) ![Logo_PubMed](https://www.vescell.health/hs-fs/hubfs/Logo_PubMed.png?width=148&height=62&name=Logo_PubMed.png) ![Logo_US Sports](https://www.vescell.health/hs-fs/hubfs/Logo_US%20Sports.png?width=196&height=72&name=Logo_US%20Sports.png) ![Logo_NIH](https://www.vescell.health/hs-fs/hubfs/Logo_NIH.png?width=370&height=58&name=Logo_NIH.png) ## Your story can help others ##### Join the **Restore the Flow** Community ##### Get our every news release and receive our product news announcements and community events. ### Disclaimer - VesCell (ACP-01) is an investigational cell therapy. It has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for commercial sale. - The safety and effectiveness of this therapy have not been established. Information on this website is for educational purposes only and should not be considered medical advice or a promotion of an unapproved product. - Access to this investigational therapy is available in Florida pursuant to state law (s. 381.985, F.S.) for eligible patients who have provided informed consent and have been advised of the investigational nature of the treatment.  ### Important Safety Data - VesCell (ACP-01) is an investigational therapy under development, not approved by the FDA, and only available in specific countries. - Treatments are subject to health regulations in Canada, Bahamas, Dominican Republic, and Switzerland, and not US FDA oversite. - Canada’s Special Access program allows unapproved treatments for serious conditions when conventional therapies have failed. - U.S. Patients travel at their own risk for treatments received abroad. - US Patients should consult with their physicians before seeking treatment abroad. - Treatments are generally out of pocket expenses and may not be covered by US insurance. ### **Treatment Risk Information** **Angiogenic Precursor Cell Treatment of Critical Limb Ischemia Decreases Ulcer Size, Amputation and Death Rate: Re-Examination of phase II ACP NO-CLI Trial Data** Fraser C Henderson\*, Ina Sarel, Kelly Tuchman, Stephen Lewis and York Hsiang Volume5-Issue2 Dates: Received: 2024-01-18 | Accepted: 2024-02-01 | Published: 2024-02-02 Pages: 092-105 Abstract Introduction: Critical limb ischemia has a prevalence in the US of 1.33%, with mortality 15-20% and major amputation 10-40% per year. Stem cell treatment has emerged as a treatment option for the 45% of patients for whom revascularization procedures are not possible. Objective: This study re-examines the data of the Phase II clinical treatment of no option Critical limb ischemia with Hemostemix’ angiogenic cell precursors, focusing upon ulcer wound healing, amputation and death rate of this cohort. Methods: Primary endpoints were changes in ulcer size and major amputation or death within one year of treatment. The secondary endpoint was change in pain level. Results: From 2015 to 2021, 67 patients with no option Critical limb ischemia were allocated to treatment with ACP-01 (46/67) or placebo (21/67). From this data, only patients who presented with wound ulcers before administration of ACP-01 were reviewed (21 treatment, 8 placebo). Ulcer size in the treated group decreased from a mean of 1.46 cm2 to 0.48 mm2 (p = 0.01) by 3 months. There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%). Change in pain was not significant in either group at 3 months, but at 1 year was improved in the placebo group (p = 0.01). Conclusion: The administration of ACP-01 within a program of careful patient follow up is safe and associated with reduced ulcer size and decreased rate of amputation and death. Consideration should be given to re-administration of stem cell treatments every 3-6 months to optimize improvement of Critical limb ischemia. Further studies, more appropriately powered, are warranted. [![VesCell Logo White](https://www.vescell.health/hubfs/VesCell%20Logo%20White.png)](https://makewebbetter-7479797.hs-sites.com/en/austin) VesCell (ACP-01) is an investigational therapy under development and not approved by the FDA. VesCell is available through special access programs that may be approved on a case-by-case basis in Canada, Bahamas and Domican Republic for treatment of no option patients suffering from CLTI, no option patients suffering from chronic stable angina, no option ischemic and non-ischemic dilated cardiomyopathy. - - - - - ###### Resources - [Story](https://www.vescell.health/our-story) - [Memberships](https://www.vescell.health/memberships) - [Events](https://www.vescell.health/events) - [Registry](https://www.vescell.health/registry) - GLOBAL ###### We're here to help 1-239-522-2906 [Customer Success: clawrence@hemostemix.com](mailto:clawrence@hemostemix.com)   Corporate Office: tsmeenk@hemostemix.com 707 7 Ave SW #1150 Calgary, AB T2P 3H6 © 2025 Hemostemix Inc. All Rights reserved. [Privacy Policy |](https://www.vescell.health/hubfs/Hemostemix_Privacy%20Notice_2025.docx?hsLang=en) [Terms & Condition](http://www.hubspot.com)